One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through ...

On the heels of a production-tinged executive order earlier this month, the Trump administration is doubling down on efforts ...

Pfizer and RemeGen's HER2 antibody-drug conjugate delivered positive phase 3 results in a bladder cancer trial in China. | ...

The FDA has lifted its 19-month clinical hold on vaginal yeast infection drug Brexafemme (ibrexafungerp), according to the ...

Just a few weeks after Omnicom announced in early December its plans to acquire fello | Craig Romanok, chief marketing ...

WuXi Biologics is giving CDMO Terumo the keys to its site in Leverkusen, Germany, with a 150 million euros ($167 million) ...

On Nov. 9, 2020, Pfizer and partner BioNTech announced that the vaccine had met the first effectiveness bar in a key study.

A kidnapped child, a husband with a double life, a treacherous murder plot unraveled when the police arrive at the perfect ...

With two concurrent FDA approvals, Incyte’s PD-1 inhibitor Zynyz has redeemed itself in anal cancer four years after an ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...